- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04496934
Physical Activity as Adjunct Treatment for Opioid Substitution Therapy
In terms of research, it is documented that exercise has a positive effect on mental disorders. Studies have shown positive correlations between physical and mental health, also among substance users. Such a study has never been performed on patients in opioid substitution therapy (OST). Documentation on the physical health of patients and the effect of exercise is very limited. Treatment of substance users is a research area with insufficient knowledge about certain treatment effects. It is important that a treatment can both support and promote the user's own resources and efforts to change their habits of substance use.
The objective of this project is to examine the effect of exercise for OST patients, measured in relation to cognitive function and physical form. The target group consists of OST patients from 18 years of age and up, of both sexes, and on stable medication. At least 60 participants should complete the project, which is designed as a controlled randomized study (RCT). Participants in the intervention group start to exercise immediately after baseline testing. Participants in the control group are on a waiting list and will start to exercise after twelve weeks. Both groups undergo testing at baseline, after three, six and 12 months. Testing consists of two parts: A battery of cognitive and psychosocial assessments and an assessment of physical variables.
The research questions of this project are important in a public health perspective. Generated knowledge can be quickly applied to local treatment institutions in Norway.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bergen, Norway
- Haukeland University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must sign a informed consent form
- Must be participating in an opioid substitution program
- Must be on a steady fixed dose of medication
- Must be at least 18 years of age
Exclusion Criteria:
- Pregnancy
- Being in opioid substitution program for less than three months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
Exercise intervention
|
Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
|
|
Active Comparator: Control
The control group is a waiting list group.
The participants will receive exercise intervention after twelve weeks of treatment as usual.
|
Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Height and weight
Time Frame: 12 weeks
|
Weight and height will be combined to report BMI in kg/m^2
|
12 weeks
|
|
Endurance
Time Frame: 12 weeks
|
Ventilatory threshold/VO2max (endurance test on treadmill)
|
12 weeks
|
|
Strength
Time Frame: 12 weeks
|
Push-ups (maximal test where the participants perform a maximum number of correct push-ups)
|
12 weeks
|
|
Balance
Time Frame: 12 weeks
|
Stork Balance Test (timed test where the goal is to keep one's balance as long as possible)
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alcohol use
Time Frame: 12 weeks
|
AUDIT-E
|
12 weeks
|
|
Drug use
Time Frame: 12 weeks
|
DUDIT-E
|
12 weeks
|
|
Executive functions
Time Frame: 12 weeks
|
Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A)
|
12 weeks
|
|
Satisfaction with life
Time Frame: 12 weeks
|
Satisfaction With Life Scale (SWLS) Values/scores:
Results (sum of scores/values): 31 - 35 Extremely satisfied 26 - 30 Satisfied 21 - 25 Slightly satisfied 20 Neutral 15 - 19 Slightly dissatisfied 10 - 14 Dissatisfied 5 - 9 Extremely dissatisfied The higher the score the better the outcome. |
12 weeks
|
|
Sleep quality
Time Frame: 12 weeks
|
Pittsburgh Sleep Quality Index (PSQI)
|
12 weeks
|
|
Attention
Time Frame: 12 weeks
|
Connors Continuous Performance Test (CPT 3)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Asgeir Mamen, PhD, Kristiania University College
- Study Director: Lars Thore Fadnes, PhD, University of Bergen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013/00731
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.